The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses feedback he’s received from colleagues at Case ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

HR, hazard ratio; IPI, ipilimumab; MSS, melanoma-specific survival; NIVO, nivolumab; NR, not reached ... the need for similar analyses with other combinations, such as NIVO + relatlimab, to better ...

How neoadjuvant immunotherapy compares with standard adjuvant immunotherapy in patients with resectable, macroscopic stage III melanoma has been unclear. New research findings are summarized in a ...

More information: Diwakar Davar et al, Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective ...